Drug Repurposing of Metabolic Agents in Malignant Glioma

Int J Mol Sci. 2018 Sep 14;19(9):2768. doi: 10.3390/ijms19092768.

Abstract

Gliomas are highly invasive brain tumors with short patient survival. One major pathogenic factor is aberrant tumor metabolism, which may be targeted with different specific and unspecific agents. Drug repurposing is of increasing interest in glioma research. Drugs interfering with the patient's metabolism may also influence glioma metabolism. In this review, we outline definitions and methods for drug repurposing. Furthermore, we give insights into important candidates for a metabolic drug repurposing, namely metformin, statins, non-steroidal anti-inflammatory drugs, disulfiram and lonidamine. Advantages and pitfalls of drug repurposing will finally be discussed.

Keywords: NSAR; disulfiram; drug repurposing; glioblastoma; glioma; lonidamine; metformin; statin.

Publication types

  • Review

MeSH terms

  • Animals
  • Antimetabolites, Antineoplastic / pharmacology
  • Antimetabolites, Antineoplastic / therapeutic use*
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Brain Neoplasms / drug therapy*
  • Brain Neoplasms / metabolism*
  • Brain Neoplasms / mortality
  • Drug Repositioning*
  • Energy Metabolism / drug effects*
  • Glioma / drug therapy*
  • Glioma / metabolism*
  • Glioma / mortality
  • Humans
  • Molecular Targeted Therapy
  • Treatment Outcome

Substances

  • Antimetabolites, Antineoplastic